EANS-News: Intercell AG / Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

Wien (euro adhoc) - WHITEHOUSE STATION, N.J. and VIENNA, June 8, 2011
- Merck (NYSE:MRK), known as MSD outside the United States and
Canada, and Intercell AG (VSE: ICLL) today announced that following a
detailed analysis of the data from the Phase II/III clinical trial
evaluating V710, an investigational vaccine for the prevention of
Staphylococcus aureus (S. aureus) infection, the independent Data
Monitoring Committee (DMC) has unanimously recommended termination of
the study.

As previously announced, following a pre-planned meeting in April,
the DMC informed Merck that the trial had not met the formal futility
criteria. However, the DMC recommended that enrollment in the Phase
II/III clinical trial be suspended pending completion by Merck of
additional analyses on the benefits and risks of vaccination.
Following further review of the statistical analyses by the DMC -
which also considered events that had occurred after the
pre-specified data cutoff date utilized for the April meeting - the
recommendation to terminate was made based upon both the observation
that V710 was unlikely to demonstrate a statistically significant
clinical benefit as well as a safety concern regarding overall
mortality and multi-organ dysfunction that occurred with greater
frequency in vaccine recipients, compared with placebo recipients.
In the additional analyses that were performed, this safety
difference was not found to be statistically significant and was also
determined not to warrant any action beyond routine safety follow-up.
Merck plans to present the final detailed findings of the clinical
trial at an upcoming medical meeting.

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market